Literature DB >> 2748510

Bezafibrate inhibits HMG-CoA reductase activity in incubated blood mononuclear cells from normal subjects and patients with heterozygous familial hypercholesterolaemia.

F Blasi1, D Sommariva, R Cosentini, B Cavaiani, A Fasoli.   

Abstract

In incubated blood mononuclear cells from normal subjects bezafibrate inhibited the incorporation of 14C-acetate into squalene, methylsterols and cholesterol. Similarly, the drug produced a sharp decrease of the incorporation of labelled 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) into non-saponifiable lipids, while the incorporation of 14C-mevalonate was unaffected by the presence of bezafibrate in the incubation mixture. This strongly suggests that bezafibrate inhibits HMG-CoA reductase activity. In cultured cells from patients with heterozygous familial hypercholesterolaemia the presence of bezafibrate in the incubation medium resulted in an inhibition of the incorporation of labelled acetate into non-saponifiable lipids. Bezafibrate then inhibits cholesterol biosynthesis in cells from normal and hypercholesterolaemic patients and this effect is likely, to contribute to the hypocholesterolaemic activity of the drug.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2748510     DOI: 10.1016/s1043-6618(89)80002-7

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  2 in total

1.  Bezafibrate fails to directly modulate HMG-CoA reductase or LDL catabolism in human mononuclear cells.

Authors:  E F Stange; M Frühholz; M Osenbrügge; F Reimann; H Ditschuneit
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

Authors:  K L Goa; L B Barradell; G L Plosker
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.